What's in Bausch & Lomb Incorporated's pipeline?

Bausch & Lomb Incorporated has 64 drugs in our index: 25 marketed, 0 filed, 20 in Phase 3, 11 in Phase 2, 7 in Phase 1.

Which companies overlap with Bausch & Lomb Incorporated's portfolio?

Top competitors by shared drug class: Allergan, Pfizer, GlaxoSmithKline, Montefiore Medical Center, Federal University of São Paulo.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bausch-lomb-incorporated.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Bausch & Lomb Incorporated — Portfolio Competitive Intelligence Brief

Bausch & Lomb Incorporated pipeline: 25 marketed, 0 filed, 20 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

25 marketed 0 filed 20 Phase 3 11 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	marketed		H1-receptor, mast cells
Loteprednol etabonate 0.5% and tobramycin 0.3%	Loteprednol etabonate 0.5% and tobramycin 0.3%	marketed
Loteprednol and tobramycin	Loteprednol and tobramycin	marketed	Corticosteroid/aminoglycoside combination	Inflammatory mediators and bacterial protein synthesis	Metabolic
Brimonidine tartrate ophthalmic solution 0.025%	Brimonidine tartrate ophthalmic solution 0.025%	marketed
Indomethacin ophthalmic solution	Indomethacin ophthalmic solution	marketed
loteprednol etabonate and tobramycin	loteprednol etabonate and tobramycin	marketed	Aminoglycoside Antibacterial [EPC]
Vehicle of Zylet	Vehicle of Zylet	marketed			Ophthalmology
bromfenac ophthalmic solution	bromfenac ophthalmic solution	marketed
Dexamethasone 0.1% and tobramycin 0.3%	Dexamethasone 0.1% and tobramycin 0.3%	marketed
instillation of NOV03	instillation of NOV03	marketed
fluocinolone acetonide intravitreal implant	fluocinolone acetonide intravitreal implant	marketed
Perfluorohexyloctane ophthalmic solution	Perfluorohexyloctane ophthalmic solution	marketed

Therapeutic area mix

Ophthalmology · 29
Ophthalmology / Allergy · 4
Other · 2
Infectious Diseases · 1
Metabolic · 1
Gastrointestinal · 1
Ophthalmology/Allergy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 5 shared drug classes
Pfizer · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Montefiore Medical Center · 3 shared drug classes
Federal University of São Paulo · 3 shared drug classes
Organon and Co · 3 shared drug classes
LEO Pharma · 3 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bausch & Lomb Incorporated:

Cite this brief

Drug Landscape (2026). Bausch & Lomb Incorporated — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bausch-lomb-incorporated. Accessed 2026-05-16.